Fig. 4

Blocking CD36:TSP-1 interactions does not inhibit VM by melanoma cells. (A) VM formation by C32 melanoma cells assessed following treatment with 150 and 1500 ng/ml TSP-1. Microscopy images are representative of VM with TSP-1 treatments (scale bar = 100 μm). Right bar graph, number of VM normalized to untreated (UNT) controls. Data are mean ± SEM from n = 3 experiments. (B) VM formation by C32 melanoma cells assessed following administration of anti-CD36 mAb (10 μg/ml) or isotype IgG1 control (10 μg/ml) prior to cell seeding for VM assay. Microscopy images are representative of VM (scale bar = 100 μm). Right bar graph, number of VM normalized to untreated (UNT) controls. Data are mean ± SEM from n = 3 experiments. (C) Left histogram, flow cytometric analysis of CD36 expression on HMVEC cells with isotype control (dotted line) and CD36 (solid line). Right bar graph, survival of HMVECs assessed without or with 1500 ng/ml TSP-1 for 6 h. Data are mean ± SEM from n = 3 experiments. (D) HMVEC angiogenesis without and with 1500 ng/ml TSP-1. Microscopy images are representative of EC angiogenesis (scale bar = 500 μm). Right bar graph is number of EC branches per well normalized to untreated (UNT) controls. Data are mean ± SEM from n = 3 experiments. *p < 0.05, t-test